Category: Health professionals
Low Carbohydrate diets, Weight management, Type 2 diabetes and Dyslipidaemia
Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia
Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. The authors claim this is misguided.
Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
Research suggests adherence to lifelong pharmacological and lifestyle treatment by people with FH is poor. This study explores the qualitative research to identify enablers and barriers to treatment adherence.
Diagnosis, management and prognosis of familial hypercholesterolaemia in a UK tertiary cardiac centre
To describe demographic characteristics, current local clinical management and outcomes for patients with familial hypercholesterolaemia (FH) managed at the Royal Brompton and Harefield NHS Foundation Trust (RBHT), a specialist UK tertiary cardiac centre.
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Familial chylomicronemia syndrome is a rare genetic disorder that is caused by loss of lipoprotein lipase activity and characterized by chylomicronemia and recurrent episodes of pancreatitis. There are no effective therapies. In an open-label study of three patients with this syndrome, antisense-mediated inhibition of hepatic APOC3 mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels.
Does diet quality or nutrient quantity contribute more to health?
Different lines of investigation suggest that “dietary quality” rather than “nutrient quantity” is a more reliable index for healthy nutrition. Any meaningful dietary intervention ought to extend far beyond the current focus on nutrient quantity and include the myriad qualitative aspects of food and food combinations, which would affect health and disease states.
Source:The Journal of Clinical Investigation
Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
An appraisal of currently available and emerging therapies for lowering LDL cholesterol, lipoprotein(a), and triglycerides for prevention of ischaemic heart disease.
Source: The Lancet
Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care
A consensus statement by HEART UK on a strategy with age appropriate guidance for managing children and young people with heterozygous FH in the UK.